Lincoln Pharmaceuticals informs about outcome of board meeting

10 Nov 2022 Evaluate
Lincoln Pharmaceuticals has informed that pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), the Board of Directors of the Company at its meeting held today have considered/ approved/ recommended the followings: The un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended on September 30, 2022 along with the limited review report from auditors thereon. In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of un-audited consolidated financial results for the quarter and half year ended on September 30, 2022. The un-audited financial results (standalone and consolidated) will be available at Company's website at www.lincolnpharma.com. Further, it has enclosed financial highlights for the aforesaid quarter. The appointment of Trusha Shah (Membership no. AS9416) as Company Secretary and Compliance Officer of the Company with effective from 10th November, 2022. A brief profile of Trusha Shah and the disclosure as required under Regulation 30(6) read with Schedule III Part A Para A (1) of the Listing Regulations and the SEBI Circular CIR/CFD/CMD/4/2015 dated 9th September 2015 is attached as Annexure A. Meeting of the Board of Directors commenced at 9.45 AM and concluded at 11.15 AM.

The above information is a part of company’s filings submitted to BSE.

Lincoln Pharma Share Price

561.65 -1.85 (-0.33%)
31-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1462.50
Dr. Reddys Lab 5784.50
Cipla 1451.25
Zydus Lifesciences 1001.15
Lupin 1587.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.